Irene J Hoogeveen1, Rixt M van der Ende1, Francjan J van Spronsen1, Foekje de Boer1, M Rebecca Heiner-Fokkema1,2, Terry G J Derks3. 1. Section of Metabolic Diseases, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, 30 001, 9700 RB, Groningen, The Netherlands. 2. Laboratory of Metabolic Diseases, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Section of Metabolic Diseases, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, 30 001, 9700 RB, Groningen, The Netherlands. t.g.j.derks@umcg.nl.
Abstract
BACKGROUND: According to the textbooks, the ketotic glycogen storage disease (GSD) types 0, III, VI, IX, and XI are associated with fasting ketotic hypoglycemia and considered milder as gluconeogenesis is intact. METHODS: A retrospective cohort study of biochemical profiles from supervised clinical fasting studies is performed in ketotic GSD patients in our metabolic center. For data analysis, hypoglycemia was defined as plasma glucose concentration <2.6 mmol/L. Total KB was defined as the sum of blood acetoacetate and β-hydroxybutyrate concentrations. If the product of glucose and KB concentrations was greater than 10, a ketolysis defect was suspected. RESULTS: Data could be collected from 13 fasting studies in 12 patients with GSD III (n = 4), GSD VI (n = 3), and GSD IX (n = 5). Six patients remained normoglycemic with median glucose concentration of 3.9 mmol/L (range, 2.8-4.6 mmol/L) and median total KB concentration of 1.9 mmol/L (range, 0.6-5.1 mmol/L). The normoglycemic patients included type VI (3 out of 3) and type IX (3 out of 5) patients. All type III patients developed ketotic hypoglycemia. Interestingly, in five patients (one GSD III, one GSD VI, and three GSD IX), the biochemical profile suggested a ketolysis defect. CONCLUSION: Normoglycemic ketonemia is a common biochemical presentation in patients with GSD types VI and IX, and ketonemia can precede hypoglycemia in all studied GSD types. Therefore, GSD VI and GSD IX should be added to the differential diagnosis of ketotic normoglycemia, and KB concentrations should be routinely measured in ketotic GSD patients.
BACKGROUND: According to the textbooks, the ketotic glycogen storage disease (GSD) types 0, III, VI, IX, and XI are associated with fasting ketotic hypoglycemia and considered milder as gluconeogenesis is intact. METHODS: A retrospective cohort study of biochemical profiles from supervised clinical fasting studies is performed in ketotic GSDpatients in our metabolic center. For data analysis, hypoglycemia was defined as plasma glucose concentration <2.6 mmol/L. Total KB was defined as the sum of blood acetoacetate and β-hydroxybutyrate concentrations. If the product of glucose and KB concentrations was greater than 10, a ketolysis defect was suspected. RESULTS: Data could be collected from 13 fasting studies in 12 patients with GSD III (n = 4), GSD VI (n = 3), and GSD IX (n = 5). Six patients remained normoglycemic with median glucose concentration of 3.9 mmol/L (range, 2.8-4.6 mmol/L) and median total KB concentration of 1.9 mmol/L (range, 0.6-5.1 mmol/L). The normoglycemic patients included type VI (3 out of 3) and type IX (3 out of 5) patients. All type III patients developed ketotic hypoglycemia. Interestingly, in five patients (one GSD III, one GSD VI, and three GSD IX), the biochemical profile suggested a ketolysis defect. CONCLUSION:Normoglycemic ketonemia is a common biochemical presentation in patients with GSD types VI and IX, and ketonemia can precede hypoglycemia in all studied GSD types. Therefore, GSD VI and GSD IX should be added to the differential diagnosis of ketotic normoglycemia, and KB concentrations should be routinely measured in ketotic GSDpatients.
Authors: Maria Clemente; Miquel Gussinyer; José Antonio Arranz; Encarnació Riudor; Diego Yeste; Marian Albisu; Antonio Carrascosa Journal: J Pediatr Endocrinol Metab Date: 2010-08 Impact factor: 1.634
Authors: M Cornblath; J M Hawdon; A F Williams; A Aynsley-Green; M P Ward-Platt; R Schwartz; S C Kalhan Journal: Pediatrics Date: 2000-05 Impact factor: 7.124
Authors: Merel R van Veen; Peter M van Hasselt; Monique G M de Sain-van der Velden; Nanda Verhoeven; Floris C Hofstede; Tom J de Koning; Gepke Visser Journal: Pediatrics Date: 2011-03-21 Impact factor: 7.124
Authors: J P Bonnefont; N B Specola; A Vassault; A Lombes; H Ogier; J B de Klerk; A Munnich; M Coude; M Paturneau-Jouas; J M Saudubray Journal: Eur J Pediatr Date: 1990-12 Impact factor: 3.183
Authors: N J Beauchamp; J Taybert; M P Champion; V Layet; P Heinz-Erian; A Dalton; M S Tanner; E Pronicka; M J Sharrard Journal: J Inherit Metab Dis Date: 2007-08-21 Impact factor: 4.982
Authors: Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson Journal: Genet Med Date: 2010-07 Impact factor: 8.822
Authors: Christiaan P Sentner; Irene J Hoogeveen; David A Weinstein; René Santer; Elaine Murphy; Patrick J McKiernan; Ulrike Steuerwald; Nicholas J Beauchamp; Joanna Taybert; Pascal Laforêt; François M Petit; Aurélie Hubert; Philippe Labrune; G Peter A Smit; Terry G J Derks Journal: J Inherit Metab Dis Date: 2016-04-22 Impact factor: 4.982